Literature DB >> 1404479

Risk factors for neuroleptic malignant syndrome.

M J Akpaffiong1.   

Abstract

Neuroleptic malignant syndrome, a rare and potentially fatal complication of antipsychotic drugs, is poorly understood. Equally poorly understood are the risk factors of neuroleptic malignant syndrome. Long-term and parenteral treatment with high doses of neuroleptic drugs are implicated as risk factors for the syndrome. Recently, attention has been drawn to the frequency of neuroleptic malignant syndrome in patients treated with a combination of haloperidol and lithium. This article reports a case in which the patient's risk factors for neuroleptic malignant syndrome included not only haloperidol and lithium but also a predisposition to substances of abuse.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404479      PMCID: PMC2571783     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  10 in total

1.  Adverse reactions in treatment with lithium carbonate and haloperidol.

Authors:  P C Baastrup; P Hollnagel; R Sorensen; M Schou
Journal:  JAMA       Date:  1976-12-06       Impact factor: 56.272

Review 2.  CLINICAL OBSERVATIONS OF THE SIDE-EFFECTS OF HALOPERIDOL.

Authors:  B Gerle
Journal:  Acta Psychiatr Scand       Date:  1964       Impact factor: 6.392

3.  Fever caused by lithium in a patient with neuroleptic malignant syndrome.

Authors:  D H Gabuzda; F R Frankenburg
Journal:  J Clin Psychopharmacol       Date:  1987-08       Impact factor: 3.153

4.  Lithium carbonate, haloperidol, and irreversible brain damage.

Authors:  W J Cohen; N H Cohen
Journal:  JAMA       Date:  1974-12-02       Impact factor: 56.272

Review 5.  Risk factors for the neuroleptic malignant syndrome.

Authors:  B Kirkpatrick; G A Edelsohn
Journal:  Psychiatr Med       Date:  1984-12

6.  Occurrence of neuroleptic malignant syndrome in a narcoleptic patient.

Authors:  S Chayasirisobhon; P Cullis; R R Veeramasuneni
Journal:  Hosp Community Psychiatry       Date:  1983-06

7.  A paradoxical response to chlorpromazine--a possible variant of the neuroleptic malignant syndrome.

Authors:  W A Price; A J Giannini
Journal:  J Clin Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.126

8.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

9.  Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.

Authors:  M Toru; O Matsuda; K Makiguchi; K Sugano
Journal:  J Nerv Ment Dis       Date:  1981-05       Impact factor: 2.254

10.  The neuroleptic malignant syndrome.

Authors:  S N Caroff
Journal:  J Clin Psychiatry       Date:  1980-03       Impact factor: 4.384

  10 in total
  1 in total

1.  Catatonic schizophrenia: therapeutic challenges and potentially a new role for electroconvulsive therapy?

Authors:  Deirdre Philbin; D Mulryan; M O'Grady
Journal:  BMJ Case Rep       Date:  2013-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.